Moreover, it has been demonstrated that pre-treatment of non-tumor HEK-293 cells with a NK-1R antagonist (before exposure to cytostatics), protected the HEK-293 cells from cytostatic toxicity (Table 1) [33]. The gene discussed is TACR1; the disease is neoplasm.